Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21566 | 0.89 | CYP1A2 (0.57) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL8793429 | 0.89 | CYP1A2 (0.52) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL29727863 | 0.89 | CYP1A2 (0.57) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL30122458 | 0.89 | CYP1A2 (0.52) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL1198631 | 0.89 | CYP1A2 (0.52) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL8155419 | 0.85 | CYP1A2 (0.48) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL6036755 | 0.84 | CYP1A2 (0.52) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL1412364 | 0.84 | CYP1A2 (0.47) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL3646028 | 0.84 | CYP1A2 (0.47) | CYP1A2TSHRCYP3A4ALDH1A1RECQL | |
| SCHEMBL2800695 | 0.84 | CYP3A4 (0.52) | CYP1A2TSHRCYP3A4ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994580-B2 | Phthalocyanine compound and method of preparing the same, color filter containing phthalocyanine compound, and coloring composition | DIC CORPORATION (JP) | 2018-06-12 | — | — | US | disclosed |
| US-20170327510-A1 | PHTHALOCYANINE COMPOUND AND METHOD OF PREPARING THE SAME, COLOR FILTER CONTAINING PHTHALOCYANINE COMPOUND, AND COLORING COMPOSITION | DIC CORPORATION (JP) | 2017-11-16 | — | — | US | disclosed |
| WO-2014096388-A2 | NOVEL BENZIMIDAZOLE DERIVATIVES AS KINASE INHIBITORS | SELVITA S.A. (PL) | 2014-06-26 | — | — | WO | disclosed |
| EP-1997809-B1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC (US) | 2014-05-14 | — | — | EP | disclosed |
| US-8518983-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-1997810-B1 | Indazoles, benzotriazoles and N-analogs thereof as p38 kinase inhibitors | ARRAY BIOPHARMA INC (US) | 2013-07-31 | — | — | EP | disclosed |
| EP-2039685-B1 | Heterobicyclic compounds as P38 inhibitors | ARRAY BIOPHARMA INC (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-8026233-B2 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2011-09-27 | — | — | US | disclosed |
| EP-1883404-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2007126871-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| EP-1606283-A4 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-05-23 | — | — | EP | disclosed |
| CN-1295207-C | Method for preparing 4-dibromo-6-nitro methylbenzene | SHANGHAI CHEMICAL REAGENT RES (CN) | 2007-01-17 | — | — | CN | disclosed |
| US-20060264431-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006122230-A1 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| EP-1606283-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2005-12-21 | — | — | EP | disclosed |
| CN-1623974-A | Method for preparing 4-dibromo-6-nitro methylbenzene | SHANGHAI INST OF CHEMICAL REAG (CN) | 2005-06-08 | — | — | CN | disclosed |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | ARRAY BIOPHARMA INC. | 2004-09-30 | — | — | US | disclosed |
| WO-2004078116-A2 | P38 INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264431-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAP3K1, MAP3K7 | CYP1A2 2572/4885TSHR 3774/4885CYP3A4 3886/4885 |
| US-20040192653-A1 | P38 inhibitors and methods of use thereof | MAPK1, MAPK3, MAPK8 | CYP1A2 2617/4885TSHR 3869/4885CYP3A4 4023/4885 |
| US-20170327510-A1 | PHTHALOCYANINE COMPOUND AND METHOD OF PREPARING THE SAME, COLOR FILTER CONTAINING PHTHALOCYANINE COMPOUND, AND COLORING COMPOSITION | KMT5C, KMT5B, MAP1LC3C | CYP1A2 3911/4885TSHR 1775/4885CYP3A4 3059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.